Formulary Drug Review: Safinamide.
作者信息
Baker Danial E, Kim Anne P
机构信息
Washington State University, Spokane, USA.
Washington State University, Yakima, USA.
出版信息
Hosp Pharm. 2017 Sep;52(8):532-543. doi: 10.1177/0018578717726046. Epub 2017 Aug 18.
Abstract
摘要
相似文献
1
Formulary Drug Review: Safinamide.处方药物审查：沙芬酰胺
Hosp Pharm. 2017 Sep;52(8):532-543. doi: 10.1177/0018578717726046. Epub 2017 Aug 18.
2
Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.甲磺酸沙芬酰胺治疗中晚期帕金森病的药代动力学药物评价。
Expert Opin Drug Metab Toxicol. 2017 Jun;13(6):693-699. doi: 10.1080/17425255.2017.1329418.
3
Safinamide: A Review in Parkinson's Disease.沙芬酰胺：帕金森病综述
CNS Drugs. 2017 Feb;31(2):169-176. doi: 10.1007/s40263-017-0408-1.
4
Safinamide for the treatment of Parkinson's disease.沙芬酰胺治疗帕金森病。
Expert Opin Investig Drugs. 2014 May;23(5):729-42. doi: 10.1517/13543784.2014.897694. Epub 2014 Mar 21.
5
Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.沙芬酰胺的药代动力学和药效学，一种具有抗帕金森病和抗惊厥活性的神经保护剂。
Pharmacol Res. 2004 Jul;50(1):77-85. doi: 10.1016/j.phrs.2003.12.004.
6
Absolute Bioavailability and Effect of Food on the Disposition of Safinamide Immediate Release Tablets in Healthy Adult Subjects.在健康成年受试者中，即刻释放型沙非酰胺片的绝对生物利用度和食物对其处置的影响。
Clin Pharmacol Drug Dev. 2013 Jan;2(1):79-89. doi: 10.1002/cpdd.2. Epub 2013 Feb 22.
7
Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.沙芬酰胺可减少帕金森病猴的运动障碍并延长 L-DOPA 的抗帕金森病作用。
Parkinsonism Relat Disord. 2013 May;19(5):508-14. doi: 10.1016/j.parkreldis.2013.01.009. Epub 2013 Feb 9.
8
Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.在早期帕金森病中作为附加疗法使用沙芬酰胺的长期疗效和安全性。
Eur J Neurol. 2013 Feb;20(2):271-80. doi: 10.1111/j.1468-1331.2012.03840.x. Epub 2012 Sep 12.
9
Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.沙芬酰胺对中晚期帕金森病异动症的长期影响：一项事后分析
J Parkinsons Dis. 2015;5(3):475-81. doi: 10.3233/JPD-150569.
10
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.司来吉兰作为左旋多巴附加治疗中晚期帕金森病的两年随机对照研究。
Mov Disord. 2014 Sep;29(10):1273-80. doi: 10.1002/mds.25961. Epub 2014 Jul 10.
引用本文的文献
1
Real life evaluation of safinamide effectiveness in Parkinson's disease.真实世界中评估沙芬酰胺在帕金森病中的疗效。
Neurol Sci. 2018 Apr;39(4):733-739. doi: 10.1007/s10072-018-3272-y. Epub 2018 Feb 13.
本文引用的文献
1
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.评估依司他宾作为左旋多巴辅助治疗帕金森病运动波动患者的安全性和疗效：一项随机临床试验。
JAMA Neurol. 2017 Feb 1;74(2):216-224. doi: 10.1001/jamaneurol.2016.4467.
2
Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis.沙芬酰胺对帕金森病波动期患者疼痛的影响：一项事后分析。
J Parkinsons Dis. 2017;7(1):95-101. doi: 10.3233/JPD-160911.
3
Absolute Bioavailability and Effect of Food on the Disposition of Safinamide Immediate Release Tablets in Healthy Adult Subjects.在健康成年受试者中，即刻释放型沙非酰胺片的绝对生物利用度和食物对其处置的影响。
Clin Pharmacol Drug Dev. 2013 Jan;2(1):79-89. doi: 10.1002/cpdd.2. Epub 2013 Feb 22.
4
Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.沙芬酰胺作为左旋多巴的附加疗法用于中晚期帕金森病波动型患者：016研究和SETTLE研究的事后分析
J Parkinsons Dis. 2016;6(1):165-73. doi: 10.3233/JPD-150700.
5
Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.沙芬酰胺对中晚期帕金森病异动症的长期影响：一项事后分析
J Parkinsons Dis. 2015;5(3):475-81. doi: 10.3233/JPD-150569.
6
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.司来吉兰作为左旋多巴附加治疗中晚期帕金森病的两年随机对照研究。
Mov Disord. 2014 Sep;29(10):1273-80. doi: 10.1002/mds.25961. Epub 2014 Jul 10.
7
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.随机试验：添加沙芬酰胺治疗伴有运动波动的帕金森病患者的左旋多巴。
Mov Disord. 2014 Feb;29(2):229-37. doi: 10.1002/mds.25751. Epub 2013 Dec 9.
8
Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers.
Pharmacology. 2013;92(3-4):207-16. doi: 10.1159/000354805. Epub 2013 Oct 11.
9
Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects.酮康唑治疗对健康成年受试者中沙非酰胺及其血浆代谢物药代动力学的影响。
Biopharm Drug Dispos. 2012 Dec;33(9):550-9. doi: 10.1002/bdd.1822. Epub 2012 Nov 19.
10
Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.在早期帕金森病中作为附加疗法使用沙芬酰胺的长期疗效和安全性。
Eur J Neurol. 2013 Feb;20(2):271-80. doi: 10.1111/j.1468-1331.2012.03840.x. Epub 2012 Sep 12.
Zotero 插件